Latest news with #PDD
Edmonton Journal
2 days ago
- General
- Edmonton Journal
Cam Tait: Public needs to bond together to convince Smith government to stop the CDB clawback
Article content After I hung up my cellphone in the Edmonton Sun newsroom in December of 2015, I didn't understand what I had just committed to. I did, however, understand it was, really really, important. Article content Article content Article content Following the 2007 death of an Edmonton woman with Downs syndrome in a group home fire, the provincial government brought in new regulations, with legislation being effective April 1, 2015. Article content Under Section 8, residences for people with developmental disabilities had to comply with numerous regulations which govern public facilities, such as industrial systems and exit signs above the doors. Article content The reaction was overwhelming. Families were getting ready to spend tens of thousands of dollars to keep their family members safe in their home. Article content I was one of eight panel members who travelled to Fort McMurray, Grande Prairie, Edmonton, Red Deer, Calgary and other Alberta centres. Article content Article content We heard from 750 people in person and another 1,300 people who answered questionnaires. Article content Article content In between the hotel lunches, the rides in cabs to the airport and over alcoholic beverages — memo to Danielle Smith: we all paid for our drinks ourselves — a unanimous tone hovered over our group. Article content Things had to change. Article content A number of our recommendations were acted upon, including a full review of the PDD program. Article content I ride that victory lap, now, as the provincial government continues to maliciously claw back a $200 cheque from the federal government, known as the Canadian Disability Benefit, from people who receive Assured Income for the Severely Handicapped payments from the province.
Yahoo
05-08-2025
- Business
- Yahoo
PDD Holdings Inc. Sponsored ADR (PDD) Outpaces Stock Market Gains: What You Should Know
In the latest close session, PDD Holdings Inc. Sponsored ADR (PDD) was up +1.8% at $112.04. The stock's change was more than the S&P 500's daily gain of 1.47%. Elsewhere, the Dow gained 1.34%, while the tech-heavy Nasdaq added 1.95%. Shares of the company have appreciated by 6.25% over the course of the past month, outperforming the Retail-Wholesale sector's loss of 1.38%, and the S&P 500's gain of 0.64%. Analysts and investors alike will be keeping a close eye on the performance of PDD Holdings Inc. Sponsored ADR in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.04, marking a 36.25% fall compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.28 billion, up 6.91% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $8.79 per share and a revenue of $59.22 billion, indicating changes of -22.35% and +8.28%, respectively, from the former year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for PDD Holdings Inc Sponsored ADR. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. PDD Holdings Inc. Sponsored ADR is currently a Zacks Rank #3 (Hold). In terms of valuation, PDD Holdings Inc. Sponsored ADR is currently trading at a Forward P/E ratio of 12.53. This signifies a discount in comparison to the average Forward P/E of 20.11 for its industry. One should further note that PDD currently holds a PEG ratio of 1.36. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Internet - Commerce industry had an average PEG ratio of 1.56 as trading concluded yesterday. The Internet - Commerce industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 153, putting it in the bottom 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PDD Holdings Inc. Sponsored ADR (PDD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Mint
23-07-2025
- Business
- Mint
PDD Analysts See HK Listing as More Likely After Auditor Change
(Bloomberg) -- PDD Holdings Inc.'s move to switch to a Hong Kong-based auditor may indicate the Chinese e-commerce firm is preparing to apply for a second listing there, according to two analysts. The parent company of budget shopping app Temu said in a filing on Wednesday that it has tapped Hong Kong-based auditors of Ernst & Young for a review of its financial statements this year. The firm previously worked with Beijing-based Ernst & Young Hua Ming LLP. Such a shift likely suggests that PDD is pursuing a listing in Hong Kong over coming months, according to Citigroup analyst Alicia Yap. 'If this proves to be true, we believe this could be viewed as a positive catalyst for the share price,' she said. PDD did not immediately reply to an emailed request for comment outside of office hours. PDD's American depositary receipts rose as much as 5.6% to the highest in two months. The firm is among the relatively few US-listed Chinese names that have yet to list in Hong Kong, a group that also includes retailer Vipshop Holdings Ltd. and tutoring firm TAL Education Group. Companies like Alibaba Group Holding Ltd., Inc. and Baidu Inc. have already secured a second listing in Hong Kong amid persistent concerns that they could get booted off American exchanges. In April, US Treasury Secretary Scott Bessent said all options are 'on the table' when asked about potential delistings of Chinese companies. A second listing would potentially enable investors of Chinese firms to convert ADRs to Hong Kong shares in the event of a US delisting. Upgrading the Hong Kong listing to a primary status — like what Alibaba did last year — will also allow mainland buyers to tap into the stock. Felix Wang, an analyst at Hedgeye Risk Management, noted that companies preparing to list in Hong Kong often engage with local auditors to comply with regulatory requirements. That was the case for both Alibaba and when they sought Hong Kong listings, he said. 'One of the frustrations on PDD in the past is the company not interested in issuing a secondary IPO' to expand its investor base, Wang said in a note. 'Is PDD changing its mind on listing in HK? It can only help with investor sentiment.' More stories like this are available on
Time of India
10-07-2025
- Health
- Time of India
Parkinson's disease: Common cough syrup revealed to slow down cognitive decline and dementia
Parkinson's disease (PD) is a progressive and complex neurodegenerative disorder that affects movement. It is narked not only by motor symptoms – such as tremors, stiffness, and bradykinesia – but also by cognitive decline. PD is also characterized by the degeneration and death of nerve cells in the brain that produce dopamine, a chemical messenger crucial for smooth and coordinated muscle movements. This loss of dopamine leads to a variety of motor and non-motor symptoms. Moreover, up to half of people with PD develop Parkinson's disease dementia (PDD) within a decade, with symptoms ranging from memory loss and confusion to hallucinations and mood disturbances. Recently, a groundbreaking phase 2 clinical trial has revealed that a common cough medicine can stabilize psychiatric symptoms and potentially slow cognitive decline in PDD patients. Read on to know more. The recent discovery According to a clinical trial, Ambroxol, a common cough medicine (used in Europe), has shown promise in slowing cognitive decline in people with Parkinson's disease dementia. A 12-month study conducted by researchers at Lawson Research Institute found that Ambroxol helped stabilise psychiatric symptoms, improved cognitive function, and protected against brain damage in genetically at-risk participants. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Usinas a gás: chave na transição energética Siemens Energy Leia mais Undo The study published in JAMA Neurology compared the outcome of the expectorant Ambroxol with a placebo among participants with Parkinson's disease dementia. While primary and secondary outcomes were similar, participants on the placebo experienced worsening neuropsychiatric symptoms compared to symptoms remaining the same in the intervention group. The results also showed a possible improvement in cognitive symptoms for people with variants of a particular gene. Understanding Parkinson's Dementia Parkinson's disease dementia is a progressive condition superimposed on the classic movement symptoms of PD. It typically manifests in the later stages of the disease and includes cognitive impairment – memory lapses, executive dysfunction, visual hallucinations, and mood disturbances like depression or apathy. Approximately 153,000 people in the UK live with PD. There is currently no cure for PDD, but patients can take medications called cholinesterase inhibitors to help manage symptoms. Existing treatments, such as cholinesterase inhibitors (e.g., rivastigmine, donepezil) and memantine, may provide some symptomatic relief but fail to halt or alter the underlying neurodegeneration. Ambroxol: From cough syrup to neuroprotection Ambroxol has been widely used in Europe for decades as a mucoactive agent – it helps clear phlegm and has an excellent safety profile. Its potential in neurodegenerative disease stems from its ability to enhance glucocerebrosidase (GCase) activity, a key enzyme encoded by the GBA1 gene. Reduced GCase activity leads to the build-up of alpha-synuclein, a hallmark of PD and PDD. By enhancing GCase, Ambroxol may promote the clearance of pathological proteins and reduce brain cell damage. Key findings from the phase 2 trial Researchers at Lawson Research Institute conducted a 12-month, randomized, placebo-controlled trial in 55 PDD patients, administering high-dose Ambroxol (525–1,050 mg/day). The major outcomes included: Symptom stabilization: Placebo participants experienced significant worsening in neuropsychiatric measures, while those on Ambroxol remained stable. Brain injury marker (GFAP): Serum GFAP – a biomarker of neuronal damage – increased in the placebo group but remained stable with Ambroxol, implying neuroprotective action. Cognitive improvement in high-risk individuals: Patients harboring GBA1 risk variants exhibited noticeable cognitive gains. Safety and tolerance: Ambroxol was generally well-tolerated, with no serious adverse effects noted. One detailed report noted that high-dose Ambroxol recipients showed improved Montreal Cognitive Assessment (MoCA) scores by approximately 2 points, while placebo subjects declined. Limitations and the way ahead While findings are promising, they come from a small, single-center Phase 2 trial with limited diversity and may not be fully statistically conclusive. Certain dose‑response relationships remain unclear, and the subset of GBA1 carriers was small – about eight participants. Researchers are planning larger Phase 3 clinical trials in 2025 to specifically evaluate cognitive outcomes and determine optimal dosing strategies. The parting thought Ambroxol's success could inspire wider interest in repurposing safe, existing medications for neurodegenerative disorders. It also supports the hypothesis that enhancing GCase activity may combat alpha-synuclein pathologies – a concept applicable to Parkinson's, dementia with Lewy bodies, and potentially Gaucher disease. Moreover, this study draws attention to the value of targeted precision medicine – showing particular promise in patients with genetic risk factors (e.g., GBA1 variants). This could pave the way for more personalized neurotherapy approaches Study: Slower memory decline in older adults linked to healthy lifestyle
Yahoo
09-07-2025
- Business
- Yahoo
PDD Holdings Inc. (PDD) Slid Amid Investment in E-Commerce Support and External Challenges
Artisan Partners, an investment management company, released its 'Artisan Developing World Fund' second quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund (Investor Class) returned 14.40% compared to 11.99% for the MSCI Emerging Markets Index. The Artisan Developing World Fund has returned 192.04% cumulatively, since June 30, 2015, compared to 60.03% for the index. Equities rose in the quarter despite uncertainty around US trade initiatives, strife in longer-dated bond markets, shifts in global currency preferences, and flash points in geopolitical conditions. US markets outperformed international markets in local currency terms for the same period. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Artisan Developing World Fund highlighted stocks such as PDD Holdings Inc. (NASDAQ:PDD). PDD Holdings Inc. (NASDAQ:PDD) is a multinational commerce group that operates Pinduoduo and Temu platforms. The one-month return of PDD Holdings Inc. (NASDAQ:PDD) was 3.05%, and its shares lost 23.00% of their value over the last 52 weeks. On July 8, 2025, PDD Holdings Inc. (NASDAQ:PDD) stock closed at $106.31 per share, with a market capitalization of $150.923 billion. Artisan Developing World Fund stated the following regarding PDD Holdings Inc. (NASDAQ:PDD) in its second quarter 2025 investor letter: "Bottom contributors to performance for the quarter included Meituan, Chinese e-commerce company PDD Holdings Inc. (NASDAQ:PDD), KE Holdings (BEKE), LVMH, Kanzhun (BOSS). PDD fell due to ongoing investment in domestic e-commerce merchant support and an increasingly complicated external environment related to tariffs and ADR delisting risk." A close-up of a customer using the company's e-commerce platform whilst shopping online. PDD Holdings Inc. (NASDAQ:PDD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 87 hedge fund portfolios held PDD Holdings Inc. (NASDAQ:PDD) at the end of the first quarter, compared to 85 in the previous quarter. In the first quarter of 2025, PDD Holdings Inc.'s (NASDAQ:PDD) revenues increased 10% year-over-year to RMB95.7 billion While we acknowledge the potential of PDD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered PDD Holdings Inc. (NASDAQ:PDD) and shared the list of best foreign stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
